A Phase 2 Study of the Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1)
A Parallel-Group, Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of the Safety and Efficacy of Oral AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy
This Phase 2, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and efficacy of oral AV078 in participants with refractory epilepsy due to tuberous sclerosis complex (TSC). Approximately 42 participants will be randomized in a 5:1 ratio to receive AV078 or placebo.
The study will include a Screening Period collecting 4 weeks of pre-treatment Baseline data on seizure frequency, and progress to a 12-week Treatment Period, followed by an in person final follow-up visit approximately 2 weeks after the last dose.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This study is a Phase 2, randomized, placebo controlled, double-blind, study that will evaluate the safety, tolerability, and efficacy of 12 weeks of treatment with AV078 (a selective inhibitor of mammalian target of rapamycin complex 1 (mTORC1) in participants with refractory epilepsy due to TSC.
Tuberous Sclerosis Complex (TSC) is a genetic disorder where mTOR1 complex 1 (or mTORC1) becomes more active than normal. This is an important cause of TSC symptoms, including epilepsy, which can be very difficult to treat.
Developing a drug to act directly on the mTORC1 complex, reducing its activity, may be an effective way to treat the unmet medical needs of patients with TSC epilepsy, potentially with fewer side effects than existing medications.
The purpose of this study is to determine, over a 12-week treatment period, if the investigational drug AV078 is safe and can reduce seizures in people with TSC. AV078, the "study drug," is a unique medication that can decrease the activity of mTORC1.
Approximately 42 participants will be enrolled and randomized in a 5:1 ratio to receive oral AV078 or matching placebo in addition to their existing stable anti-seizure medication regimen. Five participants aged 18 years and above will enrolled and dosed for at least four weeks before participants aged 12 years and above can be eligible to enroll.
The study consists of:
- A screening period of approximately 4 to 6 weeks
- A 12-week treatment period during which participants receive once-daily dosing of AV078 or placebo
- A follow-up visit approximately 2 weeks after the end of treatment
Dose adjustments of AV078 may be performed based on measured drug concentrations to achieve target exposure levels. Safety assessments will include monitoring of adverse events, laboratory tests, vital signs, electrocardiograms, and other clinical evaluations. Efficacy will be assessed primarily through changes in seizure frequency.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Davis Ryman, MD, PhD
- Telefonnummer: 510-961-1148
- E-mail: info@aeovian.com
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Key Inclusion Criteria:
- Participants aged 12 years and above.
- Diagnosis of TSC based on International TSC Consensus Group criteria.
- History of failure to adequately control seizures despite having been treated by two or more regimens of anti-seizure medications (ASMs).
- Receiving a stable dose of ASMs for at least 4 weeks at the start of the Screening Period and for the duration of the study.
Key Exclusion Criteria:
- History of any infection requiring use of antibiotics within the last four weeks.
- Current or history of any clinically significant mental or physical illness or condition other than TSC that the Investigator believes would create significant risk for participation in the study.
- Recent epilepsy surgery/major surgery or planned surgery during the study.
- Treatment with medicines which act in a similar way.
- Treatment with medicines that suppress the immune system.
- Treatment with medicines that may significantly affect the way the body handles the study drug.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: AV078
Participants will receive oral AV078 once daily in addition to their stable background anti-seizure medication regimen for 12 weeks.
Dosing will be titrated based on measured drug concentrations to achieve target exposure levels.
|
AV078 is a selective inhibitor of mammalian target of rapamycin complex 1 (mTORC1) administered orally once daily.
Dosing may be adjusted based on measured drug concentrations to achieve target exposure levels.
|
|
Placebo komparator: Placebo
Participants will receive matching oral placebo once daily in addition to their stable background anti-seizure medication regimen for 12 weeks.
Dose adjustments may be performed in a manner similar to active treatment to maintain blinding.
|
Matching oral placebo administered once daily.
The placebo is formulated to match AV078 and may undergo dose adjustments similar to active treatment to maintain blinding.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in Seizure Frequency
Tidsramme: Baseline (28-day period prior to treatment) to end of treatment (Week 12)
|
Change from Baseline in the number of seizures experienced in participants on active treatment.
The number of seizures will be recorded by participants or their caregivers using a seizure diary.
|
Baseline (28-day period prior to treatment) to end of treatment (Week 12)
|
|
Clinical Global Impression of Change (CGI-C)
Tidsramme: Week 12
|
Change from Baseline in symptoms of TSC, as evaluated by the study doctor.
|
Week 12
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Neurologiske manifestationer
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Neoplasmer
- Genetiske sygdomme, medfødte
- Neurodegenerative sygdomme
- Medfødte abnormiteter
- Heredodegenerative lidelser, nervesystem
- Neoplastiske syndromer, arvelig
- Neurokutane syndromer
- Hamartoma
- Neoplasmer, multiple primære
- Misdannelser af kortikal udvikling, gruppe I
- Misdannelser af kortikal udvikling
- Misdannelser i nervesystemet
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Lægemiddelresistent epilepsi
- Tuberøs sklerose
- Epilepsi
- Anfald
Andre undersøgelses-id-numre
- CL-078-201
- 2025-522330-31 (EudraCT nummer)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Epilepsi
-
Boston Children's HospitalRekrutteringEpilepsi | Bevægelsesforstyrrelser | Dyskinesier | Ataksi | Neurologisk lidelse | Chorea | Myoklonus | Dyskinesi | Dystoni lidelse | Epilepsi hos børn | EDS | Bevægelsesforstyrrelser hos børn | Epilepsy-dyskinesi | Epilepsi-dyskinesi synkdomForenede Stater
Kliniske forsøg med AV078
-
Aeovian Pharmaceuticals, Inc.AfsluttetSunde deltagereAustralien